Keywords
TLR9
EBV
IL-10
TGFβ
Abstract
Epstein-Barr virus-associated gastric carcinoma (EBVaGC) is the most common malignancy caused by EBV infection. Toll-like receptors (TLRs) as major components of innate immune system are crucial in the development of inflammatory processes and carcinogenesis. The aim of our study was to evaluate tissue and serum level of TLR9 in EBV-positive and EBV-negative gastric cancer patients. The study involved 30 EBV(+) and 30 EBV(-) patients. EBV DNA was detected in fresh frozen tumor tissue. In serum samples TLR9 level, transforming growth factor β (TGFβ), interleukin 10 (IL-10) and antibodies against EBV were detected using ELISA tests. TLR9 level was also measured in homogenate of tumour tissue. TLR9 level was statistically lower in EBV(+) patients both in serum and tissue, with statistically higher level in tissue than in serum. Lower level of TLR9 was accompanied by higher level of Epstein-Barr virus capsid antigen (EBVCA), Epstein-Barr virus nuclear antigen (EBNA) and early antigen (EA). A lower level of TLR9 was detected in patients with poorly differentiated cancer (G3) and greater lymph nodes involvement (N3-N4). Lower level of TLR9 in patients with EA may point to TLR9 role in reactivation of EBV infection.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre, LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Didkowska J, Wojciechowska U, Olasek P. Cancer in Poland in 2015. Warszawa: Centrum Onkologii Instytut im. M. Skłodowskiej-Curie; 2017.
3. Reza MA, Reza MH, Mehdieyeh L, Mehdi F, Hamid ZN. Evolution frequency of Merkel cell polyoma, Epstein-Barr and Mouse mammary tumor viruses in patients with Brest cancer in Kerman Southeast of Iran. Asian Pac J Cancer Prev. 2015;16(16):7351-7.
4. Chen XZ, Che H, Castro FH, Hu J, Brenner H. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine. 2015; 94(20):e792.
5. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Biological agents. Lyon: International Agency for Research on Cancer; 2012.
6. Liu S, Zhao Z, Han L, Liu S, Luo B. Epstein-Barr Virus Infection in Gastric Remnant Carcinoma and Recurrent Gastric Carcinoma in Qingdao of Northern China. PloSOne. 2016;11(2):e0148342.
7. Chen CJ, Hsu WL, Yang HI, Lee MH, Chen HC, Chien YC, You SL. Epidemiology of virus infection and human cancer. Recent Results Cancer Res. 2014;193:11-32.
8. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res. 2000;60(10):2745-8.
9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517): 202-9.
10. Cho J, Kang M, Kim KM. Epstein-Barr virus associated gastric carcinoma and specific features of the accompanying immune response. J Gastric Cancer. 2016;16(1):1-7.
11. Loganathan R, Nazeer M, Goda V, Devaraju P, Ali M, Karunakaran P, Jayaraman M. Genetic variants of TLR4 and TLR9 are risk factors for chronic Helicobacter pylori infection in South Indian tamils. Hum Immunol. 2017;78(2):216-20.
12. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol. 2005;42(8):859-67.
13. Lime WH, Kireta S, Russ R, Coates PT. Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood. 2007;109(3):1043-50.
14. Pachnia D, Drop B, Dworzańska A, Kliszczewska E, Polz-Dacewicz M. Transforming Growth Factor-β, Interleukin-10, and Serological Markers in EBV-associated Gastric Carcinoma. Anticancer Res. 2017;37(9):4853-8.
15. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow up. Eur J Surg Oncol. 2014;40(5):584-91.
16. Hu B, El Hajj NE, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251-61.
17. Fołtyn S, Strycharz-Dudziak M, Drop B, Boguszewska A, Polz-Dacewicz M. Serum EBV antibodies and LMP-1 in Polish patients with oropharyngeal and laryngeal cancer. Infect Agent Cancer. 2017;12:31.
18. Rickinson AB. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol. 2014;26:99-115.
19. Shcheblyakov DV, Logunov DY, Tukhvatulin AI, Shmarov MM, Naroditsky BS, Gintsburg AL. Toll-Like Receptors (TLRs): The Role in Tumor Progression. Acta Naturae. 2010;2(3):21-9.
20. Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, Corazzari M, et al. EBV stimulates TLR- and autophagy – dependent patways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escape. Eur J Immunol. 2013;43(1):147-58.
21. Ngan RK, Lan WH, Yip TT, Cho WC, Cheng WW, Lim CK, et al. Remerkableaplication of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann NY Acad Sci. 2001;995:73-9.
22. Căinap SS, Fetică B, Buiga R, Căinap C, Constantin AM, Şovrea AS. The prognostic role of EBER in pediatric cancer. Rom J Morphol Embroyol. 2015;56(4):1261-77.
23. Sairenji T, Tajima M, Kanamori M, Takasaka N, Gao X, Murakami M, et al. Characterization of EBV-infected epithelial cells lines from gastric cancer-bearing tissues. Curr Top Microbiol Immunol. 2001; 258:185-98.
24. Schetter A, You W, Lennette E, Goil M, Rabkin Ch. Association of Epstein-Barr virus antibody levels with precancerous gastric lesions in high-risk kohort. Cancer Sci. 2008;99(2):350-4.
25. Talar B, Czyż M. TGF-β signaling pathways in cancer. Postepy Hig Med Dosw (Online). 2013;25:1008-17.
26. Chao Y, Jing Y, Jia Y, Wang Y, Zhao C, Luo B. Conservation and mutation of viral interleukin-10 gene in gastric carcinomas and nasopharyngeal carcinomas. J Med Virol. 2011;83(4):644-50.
27. McKenzie J, Lopez-Giraldez F, Delecluse HJ, Walsh A, El-Guindy A. The Epstein-Barr virus immunoevasins BCRF1 and BPLF1 are expressed by a mechanism independent of the canonical late pre-initiation complex. PLOS Pathogens. 2016;12(11):e1006008.
28. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205-18.
29. Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:129.
30. Khan AA, Khan Z, Warnakulasuriya S. Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence? Ann Oncol. 2016;27(6):984-97.
31. Liu S, Wang X, Han L, Zhao Z, Zhao Ch, Luo B. Toll-like receptor gene polymorphisms and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma in Northern China. Saudi J Gastroenterol. 2015;21:95-103.
32. Fernandez-Garcia B1, Eiró N, González-Reyes S, González L, Aguirre A, González LO, et al. Clinical significance of Toll-like receptor 3, 4, and 9 in gastric cancer. J Immunother. 2014;37(2):77-83.
33. Kayamba V, Monze M, Asombang AW, Zyambo K, Kelly P. Serological response to Epstein-Barr virus Elaryantygen is associated with gastric cancer and human immunodeficiency virus infection in Zambian adults: a case control study. Pan Afr Med J. 2016;23:1-5.
34. Nishikawa J, Iizasa H, Yoshiyama H, Nakamura M, Saito M, Sasaki S, et al. The role of epigenetic regulations in Epstein-Barr virus-associated gastric cancer. Int J Mol Sci. 2017;18(8):E1606.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2020 Authors